To explore whether CD10 maintains CSCs by degrading the active domain of OGP, 500 × 10−9 m OGP (L2A) and OGP (Y10A), which was about 100 times more than the physiological concentration for the competitive binding assay, were added to the cocultured tumor cells and CD10+GPR77+ CAFs. The gene discussed is MME; the disease is neoplasm.